---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-26-000019"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:53:29.522484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27

## Summary
- Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.
- Adjusted EBITDA $202M (+19% YoY); adjusted diluted EPS $0.27 (+29% vs. $0.21).
- Specialty revenue +23% driven by CREXONT, BREKIYA autoinjector, and UNITHROID; Affordable Medicines +2%.
- AvKARE revenue -4% as government channel growth offset decline in low-margin distribution.
- Affirms previously announced increase in full year 2026 guidance; results matched preliminary numbers from April 22.

## SEC filing metadata
- accession: 0001723128-26-000019
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/0001723128-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/amrx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-26-000019
- JSON: https://secwatch.observer/filing/0001723128-26-000019.json
- Plain text: https://secwatch.observer/filing/0001723128-26-000019.txt

## Source-grounded claims
- claim_id: 7acfe694fc725d1c369c443a0c9c17d0ee25fa17
  claim: Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $723 million, net income $62 million, EPS $0.19. Guidance reaffirmed.
  evidence_excerpt: AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/0001723128-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.